Viatris Wins Approval for WAKIX in Japan
On September 16, Viatris (NASDAQ:VTRS) announced that its drug WAKIX has received regulatory approval from Japan's Ministry of Health, Labour and Welfare. The medication is approved to treat narcolepsy types 1 and 2 with or without cataplexy, as well as excessive daytime sleepiness associated with obstructive sleep apnea in patients undergoing airway obstruction treatment. WAKIX represents the first histamine H3 receptor antagonist/inverse agonist available for these conditions in Japan. Viatris acquired exclusive Japanese rights to WAKIX through its October 2025 acquisition of Aculys Pharma, which had licensed it from Bioprojet. The approval is a strategic milestone but financial success will depend on pricing and adoption rates. UBS has raised the price target for Viatris due to improved cost savings and growth outlooks. However, key details such as reimbursement prices or sales forecasts have not been disclosed yet.
Tickers: $VTRS
Topics: neurology pharmaceuticals specialty_pharma